Home / Investments / Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion

Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion

The biotech drugmaker has a market value of roughly $10 billion, meaning that Gilead would be paying up for the company and its prized breast-cancer drug.

About Helen Hague

Avatar

Check Also

Barclays Profit Surges But Higher Costs Weigh on Performance

Barclays shares fell early trading after the bank said costs rose on higher compensation for …

css.php
Font Resize